Click “OK” to leave this site and come back to visit us another time. Click “Cancel” to stay and learn more about how Novoeight® may be right for you.
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery
Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Esperoct® and Novoeight® are registered trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk All rights reserved. US19NEGT00102 February 2020
If you appreciate the bleed control and 104˚F storage temperature of Novoeight®, then you might want to explore Esperoct®, a new factor VIII treatment from Novo Nordisk. Esperoct® offers a longer half-life compared to standard half-life products, which may mean fewer infusions for you.